A primate researcher in Texas has admitted to fabricating data in a paper and two grant applications but won't lose his job.
The paper also fabricated other specifics, including the number of weekly doses of treatment administered to treat Mycobacterium tuberculosis, which causes tuberculosis, according to the office.
Kaushal also fabricated information in two grant applications submitted to the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, according to federal officials. One of the applications was lodged in 2019; the other was submitted in 2020.
He was identified in the paper as being affiliated with the Texas primate research center and the Tulane National Primate Research Center in Louisiana.
Dr. Larry Schlesinger, president of the Texas center, said Kaushal was disciplined with "the minimum consequences," describing what happened as "a first-time incident, and to our knowledge, the only time this has happened in Dr. Kaushal’s lab."
"Dr. Kaushal has received internal consequences, including significant oversight of his lab. Texas Biomed is confident that this will not happen again and that Dr. Kaushal can continue to lead the Southwest National Primate Research Center capably and with integrity," Schlesinger said.
The fabricated research happened before Kaushal's time with Texas Biomed, and a review of all studies carried out at the institution found them to be accurate, according to Schlesinger.
A spokesperson for the Tulane center said Kaushal conducted the research in question before he departed the institution but submitted the manuscript after his departure.
"After its publication, an anonymous complaint regarding possible research misconduct was received by Tulane. Tulane cooperated with Dr. Kaushal’s current institution in their inquiry into this matter, in adherence with standards that have been established to ensure the integrity of scientific findings and the public’s trust in those findings," the spokesperson told The Epoch Times via email.
Kaushal, the National Institute of Allergy and Infectious Diseases, and the National Institutes of Health didn't respond to requests for comment.
Some outside researchers criticized Kaushal's employer for retaining him.
The Office of Research Integrity stated that Kaushal entered into a settlement agreement to have his research supervised for one year beginning on July 22. As part of the agreement, a committee of senior faculty members at Texas Biomed will provide oversight and guidance of Kaushal's work. The panel must review each application for government grant funds.